February 24, 2025, Valencia, Spain – In a significant step towards strengthening its presence in the biotechnology and pharmaceutical sector, CURAPATH has been officially accepted as a member of the Innovation Club of the Valencian Community (CiCV) https://www.clubinnovacioncv.com/. This event took place at the recent General Assembly of the CiCV, held last Friday, February 21, in Valencia, where CURAPATH not only formally joined this prestigious group but also actively participated in the discussions and activities.
The CEO of CURAPATH, Philippe Clavel, and the CFO, Nicolas Serra, were present at the event, where Philippe Clavel received the membership diploma from the President, Paco Gavilán, and the Secretary-General of the CiCV, Joaquín Membrado. This recognition marks the beginning of a strategic collaboration in which CURAPATH joins this initiative as a leading company in the research and large-scale production of therapeutic solutions in critical areas such as oncology, neurodegenerative, infectious, and genetic diseases.
“Joining the CiCV is a key step in our commitment to innovation and technological development in the health sector. We are excited to contribute to this ecosystem and to learn from our peers in the Valencian Community,” stated Philippe Clavel.
During the Assembly, representatives from CURAPATH established significant contacts with key figures from the regional government, including Felipe Carrasco, the Regional Secretary for Industry, Energy, Internationalization, Trade, and Consumption of the Generalitat Valenciana, and Rafael Escamilla, Director General of External Relations at IVACE. Additionally, they exchanged ideas and projects with executives from top companies in the Valencian Community, strengthening their regional collaboration network.
The event brought together nearly a hundred executives and business leaders, demonstrating the dynamism and collaboration that characterize the CiCV. CURAPATH hopes that its participation in the Club and the contacts made during the Assembly will allow it to share the company’s good image at both regional and national levels as a key player in the development of innovative therapies that meet the needs of patients worldwide.
